Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$4.81 - $10.34 $75,444 - $162,182
-15,685 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$4.13 - $6.41 $64,779 - $100,540
15,685 New
15,685 $75,000
Q4 2018

Feb 14, 2019

SELL
$11.63 - $32.67 $458,140 - $1.29 Million
-39,393 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$42.06 - $62.4 $124,497 - $184,704
-2,960 Reduced 6.99%
39,393 $1.79 Million
Q1 2018

May 15, 2018

SELL
$50.12 - $67.72 $610,611 - $825,032
-12,183 Reduced 22.34%
42,353 $2.24 Million
Q4 2017

Feb 14, 2018

SELL
$57.69 - $84.58 $566,169 - $830,068
-9,814 Reduced 15.25%
54,536 $3.71 Million
Q3 2017

Nov 14, 2017

BUY
$67.17 - $84.81 $4.32 Million - $5.46 Million
64,350
64,350 $5.3 Million

Others Institutions Holding CLVS

# of Institutions
1
Shares Held
166
Call Options Held
0
Put Options Held
0

About Clovis Oncology, Inc.


  • Ticker CLVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 144,480,000
  • Market Cap $13M
  • Description
  • Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...
More about CLVS
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.